ASX - By Stock
|
PAA |
Re:
Ann: Chief Executive Officer Appointment
|
|
kpax
|
95 |
23K |
4 |
30/08/23 |
30/08/23 |
ASX - By Stock
|
95
|
23K
|
4
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Chief Executive Officer Appointment
|
|
kpax
|
95 |
23K |
14 |
30/08/23 |
30/08/23 |
ASX - By Stock
|
95
|
23K
|
14
|
|
ASX - By Stock
|
PAA |
Re:
Seventy Reason to Buy PAA
|
|
kpax
|
273 |
68K |
24 |
26/08/23 |
26/08/23 |
ASX - By Stock
|
273
|
68K
|
24
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Additional Phase 1 data suggest MPL may inhibit MND
|
|
kpax
|
380 |
85K |
23 |
24/08/23 |
24/08/23 |
ASX - By Stock
|
380
|
85K
|
23
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Additional Phase 1 data suggest MPL may inhibit MND
|
|
kpax
|
380 |
85K |
25 |
24/08/23 |
24/08/23 |
ASX - By Stock
|
380
|
85K
|
25
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Additional Phase 1 data suggest MPL may inhibit MND
|
|
kpax
|
380 |
85K |
21 |
24/08/23 |
24/08/23 |
ASX - By Stock
|
380
|
85K
|
21
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Additional Phase 1 data suggest MPL may inhibit MND
|
|
kpax
|
380 |
85K |
24 |
24/08/23 |
24/08/23 |
ASX - By Stock
|
380
|
85K
|
24
|
|
ASX - By Stock
|
PAA |
Re:
Who wants a Zoom Meeting with Management
|
|
kpax
|
28 |
5.2K |
19 |
22/08/23 |
22/08/23 |
ASX - By Stock
|
28
|
5.2K
|
19
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Additional Phase 1 data suggest MPL may inhibit MND
|
|
kpax
|
380 |
85K |
27 |
22/08/23 |
22/08/23 |
ASX - By Stock
|
380
|
85K
|
27
|
|
ASX - By Stock
|
ANZ |
Re:
News: ANZ ANZ Says Level 2 Common Equity Tier 1 Capital Ratio 13.5% As At Quarter-End
|
|
kpax
|
1 |
638 |
6 |
19/08/23 |
19/08/23 |
ASX - By Stock
|
1
|
638
|
6
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Cohort 3 Pharmacokinetics in MND Patients Completed
|
|
kpax
|
140 |
32K |
28 |
18/08/23 |
18/08/23 |
ASX - By Stock
|
140
|
32K
|
28
|
|
ASX - By Stock
|
PAA |
Re:
Ann: MND Biomarkers and Pharmacodynamics Results
|
|
kpax
|
396 |
85K |
8 |
07/08/23 |
07/08/23 |
ASX - By Stock
|
396
|
85K
|
8
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Epichem enters voluntary liquidation
|
|
kpax
|
218 |
51K |
11 |
04/08/23 |
04/08/23 |
ASX - By Stock
|
218
|
51K
|
11
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Epichem enters voluntary liquidation
|
|
kpax
|
218 |
51K |
13 |
03/08/23 |
03/08/23 |
ASX - By Stock
|
218
|
51K
|
13
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Epichem enters voluntary liquidation
|
|
kpax
|
218 |
51K |
16 |
01/08/23 |
01/08/23 |
ASX - By Stock
|
218
|
51K
|
16
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Epichem enters voluntary liquidation
|
|
kpax
|
218 |
51K |
14 |
01/08/23 |
01/08/23 |
ASX - By Stock
|
218
|
51K
|
14
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Results show MPL suppresses biomarkers associated with MND
|
|
kpax
|
200 |
43K |
19 |
11/07/23 |
11/07/23 |
ASX - By Stock
|
200
|
43K
|
19
|
|
ASX - By Stock
|
PAA |
Re:
Ann: MND Biomarkers and Pharmacodynamics Results
|
|
kpax
|
396 |
85K |
17 |
05/07/23 |
05/07/23 |
ASX - By Stock
|
396
|
85K
|
17
|
|
ASX - By Stock
|
PAA |
Re:
Ann: MND Biomarkers and Pharmacodynamics Results
|
|
kpax
|
396 |
85K |
42 |
04/07/23 |
04/07/23 |
ASX - By Stock
|
396
|
85K
|
42
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Motor Neurone Disease Phase 1/2 Clinical Trial Update
|
|
kpax
|
165 |
35K |
10 |
30/06/23 |
30/06/23 |
ASX - By Stock
|
165
|
35K
|
10
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Commencement of Cohort 3 in Phase 1/2 MND Trial
|
|
kpax
|
151 |
32K |
7 |
16/06/23 |
16/06/23 |
ASX - By Stock
|
151
|
32K
|
7
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Commencement of Cohort 3 in Phase 1/2 MND Trial
|
|
kpax
|
151 |
32K |
14 |
16/06/23 |
16/06/23 |
ASX - By Stock
|
151
|
32K
|
14
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Commencement of Cohort 3 in Phase 1/2 MND Trial
|
|
kpax
|
151 |
32K |
21 |
15/06/23 |
15/06/23 |
ASX - By Stock
|
151
|
32K
|
21
|
|
ASX - By Stock
|
PAA Biotech |
Re:
Catalysts Before October to Enact The Options
|
|
kpax
|
89 |
22K |
20 |
09/06/23 |
09/06/23 |
ASX - By Stock
|
89
|
22K
|
20
|
|
Charts
|
PAA Biotech |
Re:
GENERAL MEETING VOTING CORRECTLY
|
|
kpax
|
33 |
7.7K |
19 |
31/05/23 |
31/05/23 |
Charts
|
33
|
7.7K
|
19
|
|
ASX - By Stock
|
PAA |
Re:
Ann: MPL has anti-cancer effects across multiple cancer types
|
|
kpax
|
121 |
27K |
25 |
30/05/23 |
30/05/23 |
ASX - By Stock
|
121
|
27K
|
25
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Notice of General Meeting/Proxy Form
|
|
kpax
|
88 |
17K |
7 |
27/05/23 |
27/05/23 |
ASX - By Stock
|
88
|
17K
|
7
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Notice of General Meeting/Proxy Form
|
|
kpax
|
88 |
17K |
7 |
27/05/23 |
27/05/23 |
ASX - By Stock
|
88
|
17K
|
7
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Notice of General Meeting/Proxy Form
|
|
kpax
|
88 |
17K |
8 |
27/05/23 |
27/05/23 |
ASX - By Stock
|
88
|
17K
|
8
|
|
ASX - By Stock
|
PAA |
Re:
Ann: MPL has anti-cancer effects across multiple cancer types
|
|
kpax
|
121 |
27K |
7 |
26/05/23 |
26/05/23 |
ASX - By Stock
|
121
|
27K
|
7
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Notice of General Meeting/Proxy Form
|
|
kpax
|
88 |
17K |
9 |
26/05/23 |
26/05/23 |
ASX - By Stock
|
88
|
17K
|
9
|
|
ASX - By Stock
|
PAA |
Re:
South Korean Biotech 2023
|
|
kpax
|
46 |
9.8K |
8 |
23/05/23 |
23/05/23 |
ASX - By Stock
|
46
|
9.8K
|
8
|
|
ASX - By Stock
|
PAA |
South Korean Biotech 2023
|
|
kpax
|
46 |
9.8K |
12 |
23/05/23 |
23/05/23 |
ASX - By Stock
|
46
|
9.8K
|
12
|
|
ASX - By Stock
|
PAA |
Re:
Price manipulation
|
|
kpax
|
35 |
8.2K |
11 |
19/05/23 |
19/05/23 |
ASX - By Stock
|
35
|
8.2K
|
11
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Canine Trial Update
|
|
kpax
|
205 |
44K |
10 |
17/05/23 |
17/05/23 |
ASX - By Stock
|
205
|
44K
|
10
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Progress update on Phase 1/2 MND interim analysis
|
|
kpax
|
65 |
17K |
22 |
16/05/23 |
16/05/23 |
ASX - By Stock
|
65
|
17K
|
22
|
|
ASX - By Stock
|
PAA |
Re:
Ann: MPL has anti-cancer effects across multiple cancer types
|
|
kpax
|
121 |
27K |
13 |
10/05/23 |
10/05/23 |
ASX - By Stock
|
121
|
27K
|
13
|
|
ASX - By Stock
|
PAA Biotech |
Re:
MONEPANTEL - A Pan-Cancer Wonder Drug
|
|
kpax
|
84 |
22K |
8 |
09/05/23 |
09/05/23 |
ASX - By Stock
|
84
|
22K
|
8
|
|
ASX - By Stock
|
PAA Biotech |
Re:
MONEPANTEL - A Pan-Cancer Wonder Drug
|
|
kpax
|
84 |
22K |
16 |
09/05/23 |
09/05/23 |
ASX - By Stock
|
84
|
22K
|
16
|
|
ASX - By Stock
|
PAA Biotech |
Re:
MONEPANTEL - A Pan-Cancer Wonder Drug
|
|
kpax
|
84 |
22K |
24 |
09/05/23 |
09/05/23 |
ASX - By Stock
|
84
|
22K
|
24
|
|
ASX - By Stock
|
PAA Biotech |
Re:
Moving Forward , The Countdown Begins
|
|
kpax
|
21 |
5.9K |
21 |
07/05/23 |
07/05/23 |
ASX - By Stock
|
21
|
5.9K
|
21
|
|
ASX - By Stock
|
PAA |
Re:
Ann: MND Trial Successfully Completes Second Patient Cohort
|
|
kpax
|
52 |
12K |
15 |
28/04/23 |
28/04/23 |
ASX - By Stock
|
52
|
12K
|
15
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Canine Trial Update
|
|
kpax
|
205 |
44K |
16 |
24/04/23 |
24/04/23 |
ASX - By Stock
|
205
|
44K
|
16
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Canine Trial Update
|
|
kpax
|
205 |
44K |
20 |
24/04/23 |
24/04/23 |
ASX - By Stock
|
205
|
44K
|
20
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PharmAust launches international CEO search
|
|
kpax
|
95 |
23K |
30 |
21/04/23 |
21/04/23 |
ASX - By Stock
|
95
|
23K
|
30
|
|
ASX - By Stock
|
PAA |
Re:
Bella's Monepantel Trial
|
|
kpax
|
127 |
28K |
14 |
06/04/23 |
06/04/23 |
ASX - By Stock
|
127
|
28K
|
14
|
|
ASX - By Stock
|
PAA |
Re:
Ann: MND Trial Completes Enrolment of Cohort 2
|
|
kpax
|
104 |
28K |
16 |
30/03/23 |
30/03/23 |
ASX - By Stock
|
104
|
28K
|
16
|
|
ASX - By Stock
|
PAA |
Re:
Ann: MND Trial Completes Enrolment of Cohort 2
|
|
kpax
|
104 |
28K |
30 |
30/03/23 |
30/03/23 |
ASX - By Stock
|
104
|
28K
|
30
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Stable Patient in MND trial reaches 6-months on MPL
|
|
kpax
|
70 |
16K |
26 |
28/03/23 |
28/03/23 |
ASX - By Stock
|
70
|
16K
|
26
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Stable Patient in MND trial reaches 6-months on MPL
|
|
kpax
|
70 |
16K |
33 |
28/03/23 |
28/03/23 |
ASX - By Stock
|
70
|
16K
|
33
|
|